Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. ELAHERE (mirvetuximab soravtansine)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

ELAHERE (mirvetuximab soravtansine)

Medicine - Posted on Apr 11 2025
Active substance (DCI)
  • mirvetuximab soravtansine
history (2)
  • 4/9/25

    ELAHERE (mirvétuximab soravtansine) - Cancer de l’ovaire

    Inscription L'essentiel Avis favorable au remboursement dans l’indication « ELAHERE en monothérapie est indiqué dans le trai...
    CAV :
    54321
    icône flèche
  • 2/20/25

    ELAHERE (mirvetuximab soravtansine) - Cancer de l'ovaire

    Autorisation d’accès précoce octroyée à la spécialité ELAHERE (mirvetuximab soravtansine) dans l'indication « ELAHERE en mon...
    icône flèche
Technical information
ATC code
  • L01FX26
Manufacturer
ABBVIE
Presentation

ELAHERE 5 mg/mL, solution à diluer pour perfusion
1 flacon en verre de 20 mL (CIP : 34009 551 045 8 2)

All our publications
    Anemia and hemoglobinopathies Congenital, genetic and rare diseases Drug therapy Female genital diseases Genital cancers Metabolic diseases Paediatrics Urologic diseases - miscellaneous

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
LC7GD0UEqWS4MSf7